BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24727677)

  • 21. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.
    Cho EK; Bang SM; Ahn JY; Yoo SM; Park PW; Seo YH; Shin DB; Lee JH
    Korean J Intern Med; 2003 Mar; 18(1):13-20. PubMed ID: 12760263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
    Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
    Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immortalization of human AE pre-leukemia cells by hTERT allows leukemic transformation.
    Lin S; Wei J; Wunderlich M; Chou FS; Mulloy JC
    Oncotarget; 2016 Aug; 7(35):55939-55950. PubMed ID: 27509060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
    Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
    Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AML1-ETO inhibits acute myeloid leukemia immune escape by CD48.
    Wang Z; Guan W; Wang M; Chen J; Zhang L; Xiao Y; Wang L; Li Y; Yu L
    Leuk Lymphoma; 2021 Apr; 62(4):937-943. PubMed ID: 33225787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.
    Dunne J; Gascoyne DM; Lister TA; Brady HJ; Heidenreich O; Young BD
    Cancer Res; 2010 May; 70(10):3985-95. PubMed ID: 20460523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activated leukemic oncogenes AML1-ETO and c-kit: role in development of acute myeloid leukemia and current approaches for their inhibition.
    Rulina AV; Spirin PV; Prassolov VS
    Biochemistry (Mosc); 2010 Dec; 75(13):1650-66. PubMed ID: 21417999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia.
    Barbetti V; Tusa I; Cipolleschi MG; Rovida E; Dello Sbarba P
    Cell Death Dis; 2013 Mar; 4(3):e536. PubMed ID: 23492767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.
    Vegi NM; Klappacher J; Oswald F; Mulaw MA; Mandoli A; Thiel VN; Bamezai S; Feder K; Martens JHA; Rawat VPS; Mandal T; Quintanilla-Martinez L; Spiekermann K; Hiddemann W; Döhner K; Döhner H; Stunnenberg HG; Feuring-Buske M; Buske C
    Cell Rep; 2016 Jul; 16(2):498-507. PubMed ID: 27346355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell.
    Shima T; Miyamoto T; Kikushige Y; Yuda J; Tochigi T; Yoshimoto G; Kato K; Takenaka K; Iwasaki H; Mizuno S; Goto N; Akashi K
    Exp Hematol; 2014 Nov; 42(11):955-65.e1-5. PubMed ID: 25101977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia.
    Jin W; Wu K; Li YZ; Yang WT; Zou B; Zhang F; Zhang J; Wang KK
    Oncogene; 2013 Apr; 32(15):1978-87. PubMed ID: 22641217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.
    Pulikkan JA; Madera D; Xue L; Bradley P; Landrette SF; Kuo YH; Abbas S; Zhu LJ; Valk P; Castilla LH
    Blood; 2012 Jul; 120(4):868-79. PubMed ID: 22613795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amyloid precursor protein cooperates with c-KIT mutation/overexpression to regulate cell apoptosis in AML1-ETO-positive leukemia via the PI3K/AKT signaling pathway.
    Yu G; Yin C; Jiang L; Zheng Z; Wang Z; Wang C; Zhou H; Jiang X; Liu Q; Meng F
    Oncol Rep; 2016 Sep; 36(3):1626-32. PubMed ID: 27460334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
    Miyamoto T; Nagafuji K; Akashi K; Harada M; Kyo T; Akashi T; Takenaka K; Mizuno S; Gondo H; Okamura T; Dohy H; Niho Y
    Blood; 1996 Jun; 87(11):4789-96. PubMed ID: 8639850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.
    DeKelver RC; Lewin B; Lam K; Komeno Y; Yan M; Rundle C; Lo MC; Zhang DE
    PLoS Genet; 2013; 9(10):e1003765. PubMed ID: 24130502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The RUNX1-ETO fusion protein trans-activates c-KIT expression by recruiting histone acetyltransferase P300 on its promoter.
    Chen G; Liu A; Xu Y; Gao L; Jiang M; Li Y; Lv N; Zhou L; Wang L; Yu L; Li Y
    FEBS J; 2019 Mar; 286(5):901-912. PubMed ID: 30637949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Establishment of leukemia cell model with inducible AML1-ETO expression and its effect on fatty acid metabolism in leukemia cells].
    Xie WQ; Yang X; Gu RX; Tian Z; Xing HY; Tang KJ; Rao Q; Qiu SW; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):366-372. PubMed ID: 37550185
    [No Abstract]   [Full Text] [Related]  

  • 40. A minicircuitry comprised of microRNA-9 and SIRT1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.
    Zhou L; Fu L; Lv N; Chen XS; Liu J; Li Y; Xu QY; Huang S; Zhang XD; Dou LP; Wang LL; Li YH; Yu L
    Eur Rev Med Pharmacol Sci; 2017 Feb; 21(4):786-794. PubMed ID: 28272704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.